Immunomodulatory role of an Ayurvedic formulation on imbalanced immune-metabolics during inflammatory responses of obesity and pre-diabetic disease

Obesity and related type 2 diabetes are associated with a low level chronic inflammatory state with disease status increasing at epidemic proportions worldwide. It is now universally accepted that the underlying immune-inflammatory responses mediated within the adipose tissue in obesity are central to the development of disease. Once initiated, chronic inflammation associated with obesity leads to the modulation of immune cell function. In the present study we aimed to investigate the effect of an ayurvedic formulation (named as Kal-1, an abbreviation derived from the procuring source) on diet-induced obesity and type II diabetes using C57BL/6J mice. The study was planned into two groups using obese and pre-diabetic mouse model. The mice were fed on high-fat with increased diet and, different amounts (5, 20 and 75 {\mu}g) of Kal-1 were given with disease progression for 21 weeks in first group whereas mice were first put on the same diet for 21 weeks and then treated with same amounts of Kal-1. A significant reduction in body weight and fat pads, fasting blood glucose levels, insulin levels and biochemical parameters like triglycerides and cholesterol were observed in obese and diabetic mice+Kal-1 than control (lean) mice fed on low fat diet, though the optimum amounts of Kal-1 were 20 and 75 {\mu}g in first and second group respectively. A noteworthy immunological correction in important readouts viz. resistin, leptin, HMW adiponection and an array of pro- & anti-cytokines (IL-4, IL-10, IL-1{\alpha}, IL-1{\beta}, IL-4, IL-6, IL-10, TNF-{\alpha} and MCP-1) was also observed in both the groups with the mentioned amount of Kal-1. We conclude that Kal-1 has immunomodulatory potential for diet-induced obesity and associated metabolic disorders.

💡 Research Summary

The study investigates the immunomodulatory and metabolic effects of an Ayurvedic polyherbal formulation, designated Kal‑1, in mouse models of diet‑induced obesity and pre‑diabetes. Using C57BL/6J mice, the authors designed two experimental paradigms. In the first (preventive) arm, mice received a high‑fat, high‑sugar (HFD) diet together with daily oral doses of Kal‑1 at 5 µg, 20 µg, or 75 µg for 21 weeks. In the second (therapeutic) arm, mice were fed the same HFD for 21 weeks to establish obesity and metabolic dysfunction, after which the same Kal‑1 doses were administered for an additional 21 weeks. A low‑fat diet (LFD) fed cohort served as the lean control.

Body weight, visceral fat pad mass, fasting glucose, serum insulin, triglycerides, and total cholesterol were markedly elevated in HFD‑only mice. Kal‑1 treatment produced dose‑dependent reductions in these parameters. The optimal preventive dose was 20 µg, which significantly blunted weight gain, reduced epididymal and retroperitoneal fat, and restored fasting glucose, insulin, and lipid levels to values comparable with LFD controls. In the therapeutic setting, the highest dose (75 µg) achieved the greatest reversal of established obesity‑related metabolic disturbances.

Immunologically, HFD mice displayed the classic dysregulated adipokine profile: increased leptin and resistin, and decreased high‑molecular‑weight (HMW) adiponectin. Kal‑1 normalized leptin and resistin concentrations and rescued HMW adiponectin levels. A broad cytokine panel measured in serum revealed elevated pro‑inflammatory mediators (IL‑1α, IL‑1β, IL‑6, TNF‑α, MCP‑1) in HFD mice, while anti‑inflammatory cytokines (IL‑4, IL‑10) were suppressed. Kal‑1 administration shifted this balance: pro‑inflammatory cytokines were significantly reduced, and IL‑4/IL‑10 were markedly increased, indicating a re‑polarization of the immune environment toward an anti‑inflammatory state.

The authors conclude that Kal‑1 possesses potent immunomodulatory activity capable of attenuating diet‑induced metabolic inflammation, thereby improving obesity‑related phenotypes and pre‑diabetic markers. However, several limitations temper the impact of the findings. The exact phytochemical constituents responsible for the observed effects remain unidentified; Kal‑1 is a complex mixture of herbal extracts, and without component‑level analysis, reproducibility and mechanistic insight are limited. The study is confined to murine models, and translational relevance to human obesity and type‑2 diabetes is unproven. Safety and toxicity assessments are superficial; long‑term administration data are lacking. Moreover, immune profiling is restricted to circulating cytokines, without tissue‑specific analysis of macrophage polarization or T‑cell subsets within adipose depots.

Future work should focus on (1) phytochemical fractionation and identification of active molecules, (2) elucidation of signaling pathways modulated by Kal‑1 (e.g., NF‑κB inhibition, PPARγ activation, JNK suppression), (3) detailed histological and flow‑cytometric evaluation of adipose immune cell infiltrates, and (4) well‑designed clinical trials to determine optimal dosing, efficacy, and safety in humans. If these steps confirm the preclinical promise, Kal‑1 could represent a novel, plant‑based therapeutic avenue that bridges traditional Ayurvedic knowledge with modern metabolic disease management.